<DOC>
	<DOCNO>NCT01541371</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness paliperidone extended-release ( ER ; design slowly release drug body extend period time ) tablets participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusions [ false belief hold face strong differ evidence , especially symptom psychiatric disorder ] hallucination [ imagine thing ] , withdrawal self ) satisfy prior antipsychotic ( agent control agitate psychotic behavior , alleviate acute psychotic state , reduce psychotic symptom , exert quiet effect ; olanzapine , quetiapine risperidone ) taking . The safety tolerability paliperidone ER tablet also assess .</brief_summary>
	<brief_title>A Study Flexibly Dosed Paliperidone Extended Release Tablets Participants With Schizophrenia</brief_title>
	<detailed_description>This open label ( people know identity intervention ) , prospective ( study follow participant forward time ) , non-randomized ( study drug assign chance , participant may choose group want , may assign group researcher ) , single-arm ( get one dose medicine ) multi-center ( one hospital medical school team work medical research study ) study design determine efficacy , tolerability safety flexible dosage paliperidone ER tablets treatment participant schizophrenia satisfied prior antipsychotic . The duration study 12 week . All participant give paliperidone ER 3 milligram ( mg ) 6 mg 9 mg 12 mg oral ( mouth ) tablets depend Investigator 's discretion daily 12 week ; initial dose paliperidone ER 6 mg/day . The primary objective evaluate efficacy treatment paliperidone ER use Positive Negative Symptom Scale ( PANSS ) total score . Participants safety tolerability monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Participants meet Diagnostic Statistical Manual Mental DisordersIV ( DSMIV ) diagnosis criterion schizophrenia Participant receive full course treatment ( 68 week ) correct dose ( dose range recommend instruction ) Risperdal , Zyprexa Seroquel enrollment , poorly control change medication unsatisfying efficacy , tolerability safety issue , reason Participant nonacute phase screen receive treatment three antipsychotic within 4 week enrollment state illness relatively stable 7 . Female participant must postmenopausal least 1 year , surgically sterile , abstinent , , sexually active , agree practice effective method birth control entry throughout study . Effective method birth control include prescription hormonal contraceptive , contraceptive injection , intrauterine device , double barrier method , contraceptive patch male partner sterilization . Female participant must also negative urine pregnancy test screen Participant willing could complete questionnaire Participant receiving treatment clozapine risperidone microspheres injection ( Hengde ) within 3 month screen Participant history seizure except febrile convulsion ( seizures occur febrile episode [ fever ] ) Participant refractory schizophrenia ( previous treatment unsatisfied efficacy 2 2 kind antipsychotic different chemical structure adequate dose duration ) Participant receive electric shock treatment within 1 month screen Participant serious , unstable physical disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone extended-release tablet</keyword>
</DOC>